TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF NASAL SPRAY MARKET 21
1.4 CURRENCY AND PRICING 22
1.5 LIMITATION 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHIC SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 RESEARCH METHODOLOGY 28
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.7 SECONDARY SOURCES 32
2.8 ASSUMPTIONS 32
3 MARKET OVERVIEW 33
3.1 DRIVERS 35
3.1.1 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 35
3.1.2 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 36
3.1.3 INCREASE IN INFECTION & ALLERGIC CASES 37
3.2 RESTRAINTS 37
3.2.1 PRODUCT RECALLS 37
3.3 OPPORTUNITIES 38
3.3.1 NEW RISING DEMAND FOR SELF ADMINISTRATIVE DRUG DELIVERY 38
3.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 38
3.4 CHALLENGES 39
3.4.1 REGULATORY HURDLES 39
4 EXECUTIVE SUMMARY 40
5 PREMIUM INSIGHTS 43
?
6 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE 45
6.1 OVERVIEW 46
6.2 DECONGESTION NASAL SPRAY 48
6.3 SALT WATER SOLUTION/ SALINE NASAL SPRAY 49
6.4 STEROID NASAL SPRAY 51
6.5 OTHERS 52
7 EUROPE N ASAL SPRAY MARKET, BY CONTAINER DESIGN 53
7.1 OVERVIEW 54
7.2 PRESSURIZED CANISTERS 56
7.3 PUMP BOTTLES 57
8 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM 58
8.1 OVERVIEW 59
8.2 UNIT/SINGLE DOSE 61
8.3 BI DOSE 63
8.4 MULTI DOSE 64
9 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 66
9.1 OVERVIEW 67
9.2 ANTIHISTAMINE 69
9.3 NASAL STEROIDS 71
9.4 MAST CELL INHIBITOR 72
9.5 ANTICHOLINERGIC 73
10 EUROPE NASAL SPRAY MARKET, BY APPLICATION 74
10.1 OVERVIEW 75
10.2 ALLERGIC AND NON-ALLERGIC RHINITIS 77
10.3 NASAL CONGESTION 79
10.4 CENTRAL NERVOUS SYSTEM DISORDERS 80
10.5 VACCINATION 81
10.6 OTHERS 82
11 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION MODE 83
11.1 OVERVIEW 84
11.2 PRESCRIPTION BASED 86
11.3 OVER THE COUNTER 87
?
12 EUROPE NASAL SPRAY MARKET, BY END USER 89
12.1 OVERVIEW 90
12.2 HOSPITALS 92
12.3 CLINICS 93
12.4 HOME CARE SETTINGS 94
12.5 COMMUNITY HEALTH CARE 95
13 EUROPE NASAL SPRAY MARKET, BY GEOGRAPHY 96
13.1 EUROPE 96
13.1.1 STRICT GOVERNMENT REGULATIONS 96
13.1.2 GERMANY 105
13.1.3 U.K. 109
13.1.4 FRANCE 113
13.1.5 ITALY 117
13.1.6 SPAIN 121
13.1.7 SWITZERLAND 125
13.1.8 NETHERLANDS 129
13.1.9 BELGIUM 133
13.1.10 RUSSIA 137
13.1.11 TURKEY 141
13.1.12 REST OF EUROPE 145
14 EUROPE NASAL SPRAY MARKET, COMPANY LANDSCAPE 146
14.1 COMPANY SHARE ANALYSIS; EUROPE 146
15 COMPANY PROFILE 147
15.1 PFIZER INC. 147
15.1.1 COMPANY OVERVIEW 147
15.1.2 REVENUE ANALYSIS 147
15.1.3 COMPANY SHARE ANALYSIS 148
15.1.4 PRODUCT PORTFOLIO 149
15.1.5 RECENT DEVELOPMENTS 149
15.2 CIPLA INC. 150
15.2.1 COMPANY OVERVIEW 150
15.2.2 REVENUE ANALYSIS 150
15.2.3 COMPANY SHARE ANALYSIS 151
15.2.4 PRODUCT PORTFOLIO 151
15.2.5 RECENT DEVELOPMENTS 152
?
15.3 BAYER AG 153
15.3.1 COMPANY OVERVIEW 153
15.3.2 REVENUE ANALYSIS 153
15.3.3 COMPANY SHARE ANALYSIS 154
15.3.4 PRODUCT PORTFOLIO 154
15.3.5 RECENT DEVELOPMENTS 154
15.4 INNOVUS PHARMACEUTICALS, INC. 155
15.4.1 COMPANY OVERVIEW 155
15.4.2 REVENUE ANALYSIS 155
15.4.3 COMPANY SHARE ANALYSIS 156
15.4.4 PRODUCT PORTFOLIO 156
15.4.5 RECENT DEVELOPMENTS 156
15.5 GLAXOSMITHKLINE PLC. 157
15.5.1 COMPANY OVERVIEW 157
15.5.2 REVENUE ANALYSIS 157
15.5.3 PRODUCT PORTFOLIO 158
15.5.4 RECENT DEVELOPMENTS 158
15.6 ADAPT PHARMA, INC. 159
15.6.1 COMPANY OVERVIEW 159
15.6.2 GEOGRAPHIC PRESENCE 159
15.6.3 PRODUCT PORTFOLIO 160
15.6.4 RECENT DEVELOPMENTS 160
15.7 AISHWARYA GROUP 161
15.7.1 COMPANY OVERVIEW 161
15.7.2 PRODUCT PORTFOLIO 161
15.7.3 RECENT DEVELOPMENTS 161
15.8 ALLERGAN 162
15.8.1 COMPANY OVERVIEW 162
15.8.2 REVENUE ANALYSIS 162
15.8.3 PRODUCT PORTFOLIO 162
15.8.4 RECENT DEVELOPMENTS 163
15.9 ARIUS FORMULATIONS PVT LTD 164
15.9.1 COMPANY OVERVIEW 164
15.9.2 PRODUCT PORTFOLIO 164
15.9.3 RECENT DEVELOPMENTS 164
15.10 AURENA 165
15.10.1 COMPANY OVERVIEW 165
15.10.2 GEOGRAPHIC PRESENCE 165
15.10.3 PRODUCT PORTFOLIO 166
15.10.4 RECENT DEVELOPMENTS 166
15.11 CATALENT, INC 167
15.11.1 COMPANY OVERVIEW 167
15.11.2 REVENUE ANALYSIS 167
15.11.3 PRODUCT PORTFOLIO 168
15.11.4 RECENT DEVELOPMENTS 168
15.12 EGALET CORPORATION 169
15.12.1 COMPANY OVERVIEW 169
15.12.2 REVENUE ANALYSIS 169
15.12.3 PRODUCT PORTFOLIO 170
15.12.4 RECENT DEVELOPMENTS 170
15.13 J PHARMACEUTICALS 171
15.13.1 COMPANY OVERVIEW 171
15.13.2 PRODUCT PORTFOLIO 171
15.13.3 RECENT DEVELOPMENTS 171
15.14 LEEFORD HEALTHCARE LTD 172
15.14.1 COMPANY OVERVIEW 172
15.14.2 GEOGRAPHIC PRESENCE 172
15.14.3 PRODUCT PORTFOLIO 173
15.14.4 RECENT DEVELOPMENTS 173
15.15 MYLAN N.V. 174
15.15.1 REVENUE ANALYSIS 174
15.15.2 PRODUCT PORTFOLIO 175
15.15.3 RECENT DEVELOPMENTS 175
15.16 SANDOZ INTERNATIONAL GMBH 176
15.16.1 COMPANY OVERVIEW 176
15.16.2 GEOGRAPHIC PRESENCE 176
15.16.3 PRODUCT PORTFOLIO 177
15.16.4 RECENT DEVELOPMENTS 177
15.17 ST. RENATUS 178
15.17.1 COMPANY OVERVIEW 178
15.17.2 PRODUCT PORTFOLIO 178
15.17.3 RECENT DEVELOPMENTS 178
15.18 TEVA PHARMACEUTICAL INDUSTRIES LTD. 179
15.18.1 COMPANY OVERVIEW 179
15.18.2 REVENUE ANALYSIS 179
15.18.3 PRODUCT PORTFOLIO 180
15.18.4 RECENT DEVELOPMENTS 180
?
15.19 ULTRATECH INDIA LIMITED 181
15.19.1 COMPANY OVERVIEW 181
15.19.2 PRODUCT PORTFOLIO 181
15.19.3 RECENT DEVELOPMENTS 181
16 RELATED REPORTS 182